




**Test and Provide Rapid Access to Treatment
And Retain in Care (Test and Treat)**

Jeffrey Beal, MD, AAHIVS, Medical Director

Florida Department of Health
Bureau of Communicable Diseases
HIV/AIDS Section


Division of Disease Control and Health Protection
To protect, promote and improve the health of all people in Florida through integrated state, county and community efforts.

1




Discussion Topics

- Overview 2016 Florida HIV/STI Data
- Describe each component of Florida's plan to eliminate new HIV infections and reduce HIV related deaths
- Test and Treat rationale and program description



Florida Department of Health
HIV/AIDS Section
Division of Disease Control and Health Protection


To protect, promote and improve the health of all people in Florida through integrated state, county, and community efforts.



The Epidemic in Florida


Florida	2015	2016	Trend
Population in Millions	19.9 million (56% White, 16% Black, 24% Hispanic, 2% Other)	20.2 million (54% White, 15% Black, 29% Hispanic, 3% Other)	1.8% increase
Newly Diagnosed HIV cases	4,708	4,972	5.6% increase
Newly Diagnosed AIDS cases	2,129	2,119	-0.5% decrease
Pediatric AIDS cases diagnosed	3	2	-33.3% decrease
Perinatal HIV Cases born in Florida	9	8	-11.1% decrease
People diagnosed & living with HIV (Prevalence)	111,900 (29% White, 47% Black, 22% Hispanic, 2% Other)	114,800 (29% White, 46% Black, 23% Hispanic, 2% Other)	2.6% increase
HIV prevalence estimate (includes diagnosed + unaware)	127,900 (12.4% unaware of status)	135,986 (15.6% unaware of status)	6.3% increase
HIV-related deaths	873	864	-1.0% decrease


1



Florida STI Epidemic 2016

4





Florida's Plan to Eliminate HIV Transmission and Reduce HIV-related Deaths



Four Key Components

1. Implement routine HIV and Sexually Transmitted Infection (STI) screening in healthcare settings/targeted testing in non-health care settings
2. Test and provide rapid access to treatment and retain in care
3. Improve access to antiretroviral pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP)
4. Increase community outreach and messaging

7

Test and Treat Rationale




- Antiretroviral (ART) as early as possible after acquiring HIV infection → better health outcomes, reducing HIV-related morbidity or mortality^[1,2]
- ART → ↓ viral load → ↓ HIV transmission to the uninfected sexual partner in HIV-discordant couples^[3-5]
- Results of mathematical models support universal and repeated HIV testing followed by immediate ART could substantially ↓ HIV incidence at the population level^[6]

1. Daniel C et al. N Engl J Med 2015;373(9):828-32. 2. Lundgren JD, et al. J Med 2015;373(9):795-807. 3. Atta S, et al. AIDS. 2009;23(11):1397-404. 4. Cohen MS, et al. N Engl J Med. 2011;365(6):493-505. 5. Donnell D, et al. Lancet. 2010;375(9731):2092-8. 6. Granich RM, et al. Lancet. 2009; 373(9657):48-57.

8


Time to Viral Load Suppression by ART Initiation Strategy: SFGH 2006–2014



Pficher, Christopher D.; Ospina-Norvell, Clarissa; Dasgupta, Aditi; Jones, Diane; Harbogensis, Wendy; Torres, Sandra; JAIDS Journal of Acquired Immune Deficiency Syndromes. 74(1):44-51, January 1, 2017.

9


Conclusions



- It was feasible to implement same-day ART initiation for outpatients with newly diagnosed HIV in a well resourced, public health clinic setting
- Same day ART was highly acceptable to both patients and providers
- Same day ART was associated with improved rates of virologic suppression

Pficher, Christopher D., Ospina-Norvell, Clarissa, Dasgupta, Aditi, Jones, Diane, Hartogensis, Wendy, Torres, Sandra; JACS Journal of Acquired Immune Deficiency Syndromes, 74(1):44-51, January 1, 2017. 10


Conclusions (continued)



- No excess toxicity or other adverse effects of starting ART immediately at the first visit were seen
- Expansion of the RAPID model citywide in 2015

Pficher, Christopher D., Ospina-Norvell, Clarissa, Dasgupta, Aditi, Jones, Diane, Hartogensis, Wendy, Torres, Sandra; JACS Journal of Acquired Immune Deficiency Syndromes, 74(1):44-51, January 1, 2017. 11

Florida's Test and Treat (T&T) Initiative




Two- Phased Approach:

- 1st phase - Eligible Metropolitan Areas (EMA's) and County Health Department (CHD) clinics
- 2nd phase - Expansion to CHD contracted community HIV clinics

Goal – reduce time from HIV diagnosis or returning to care to initiation of ART and achievement of an undetectable HIV viral load

Test and Treat guidance available to all clinics

12


Florida's Test and Treat (T&T) Program 

T&T is a clinical program providing:

- Immediate linkage to care
- Access to medication for those newly diagnosed and those returning to care after a gap in services
- Support of retention and engagement specialty staffs

The program benefits the patient's health and the community.

13


Florida's Test and Treat Initiative cART 

Discussion of medication options (30 day starter packs):

- dolutegravir (DTG, *Tivicay*®) + tenofovir alafenamide/emtricitabine (TAF/FTC, *Descovy*®) once daily with or without food
- darunavir/cobicistat (DRV/COBI, *Prezcobix*®) + tenofovir alafenamide/emtricitabine (TAF/FTC, *Descovy*®) once daily with food
- elvitegravir (EVG) + TAF + FTC + COBI (*Genvoya*®) once daily with food

Estimate 915 enrolled as of Sep 2017


14

Miami-Dade Test and Treat Program Referral and Linkage Process 


<ul style="list-style-type: none"> • Before TNT • Pt. tests for HIV • Returns in 10 days for results. • Referred to provider agency. • Case management appointment given 2 weeks (or more) away. • Case manager assesses for financial eligibility & ADAP; refers to Doctor; appointment given for 2 weeks (or more) away. • Doctor orders labs, patient is scheduled for return appointment in 2 weeks. • Doctor writes script at return appt. • Pt. takes script to pharmacy. <p style="color: red; font-weight: bold; font-size: small;">Up to 3 months</p>	<ul style="list-style-type: none"> • After TNT • Pt. tests for HIV; preliminary results positive. • Pt accepts Test and Treat. • Pt. is escorted to case management agency where eligibility is established. • Pt. is seen by doctor and labs done. • Doctor writes script. • Medical case manager escorts Pt. to on site pharmacy to obtain 30 day supply of medication. <p style="color: red; font-weight: bold; font-size: small;">< 7 days (most same or next day)</p>
--	---

15


Miami-Dade Test and Treat Program Indicators



Viral Suppression:
Avg. 58 days – From baseline to 1st undetectable VL <200 copies/mL.
 Range: 14 - 179 days
 38 of 50 Pts. Suppressed
 10 waiting for 2nd VL
 2 not suppressed but show decreasing VL.



Time from Arrival (JMH) to Dispense date




Time from Date of Script to Dispense Date

Retention Rate:
97%

Rapid Test to Script: 9 days
Script to Dispense: 2 days
SFAN to Provider: 1 day
FDOH to SFAN: 3 days

5 acute cases identified (10%) and now have suppressed viral load.




Broward-Test and Treat Program



- Rapid HIV Test Site Locations – 12 locations
- Ryan White Medical Clinic Providers – 6 locations
- Test and Treat started May 1, 2017
- Total number of patients enrolled through September 27, 2017 = 440

17

Broward-Test and Treat Program Totals May 1st - September 27th, 2017



TOTAL NUMBER REFERRED TO TEST AND TREAT		440
Total Enrolled:	382	87%
Newly diagnosed:	200	52%
Previous positives:	182	48%
REFUSED:	24	5%
Total on ART:	356	93%
Total not on ART:	12	3%
INELIGIBLE:	34	8%
Jail	2	6%
OOJ	24	71%
Negative	7	21%
Deceased	1	3%


18



Discussion

Division of Disease Control and Health Protection
To protect, promote and improve the health of all people in Florida through integrated state, county and community efforts

19



Florida Department of Health:
HIV/AIDS Medical Section

Contact: 850-245-4334

Jeffrey Beal, MD, AAHIVS
Cell: 850-519-3734
Jeff.Beal@flhealth.gov

Debra Taylor, RN, MPA, ASQ-CQIA
Ext. 4488
Debbie.Taylor@flhealth.gov

Roselyn Jasmin, Admin. Asst.
Ext. 2514
Roselyn.Jasmin@flhealth.gov

20
